Investor Relations Home

Webcast ImageWebcast
NeuroDerm Q4 and Full Year 2016 Financial Results (Live)
03/30/17 at 8:30 a.m. ET

NeuroDerm Q4 and Full Year 2016 Financial Results
Thursday, March 30, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Download Documentation NeuroDerm March 2017 Corporate Presentation

Recent News

More >>
03/21/17NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
REHOVOT, Israel, March 21, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will report financial results for the fourth quarter and fiscal year of 2016 before the market opens on Thursday, March 30, 2017. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To acce... 
Printer Friendly Version
03/01/17NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - - The trial also showed statistically significant reduction in troublesome dyskinesia and a complete reduction of OFF-time to zero hours in 66% of responders (post hoc sub-groups analyses) - - Company to host conference call and webcast today at 8:30 a.m. ET- REHOVOT, Israel, March 01, 2017 (GL... 
Printer Friendly Version
02/27/17NeuroDerm CEO to Present at Upcoming Investor Conferences
REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017.  Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET. 29th Annual R... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
03/30/17 8:30 a.m. ET
NeuroDerm Q4 and Full Year 2016 Financial Results